Balatonfueredi Allami Szivkorhaz — Clinical Trial Site

9 Registered trials

5 Currently recruiting

Organisation

Balatonfueredi Allami Szivkorhaz

Location

Balatonfured, Hungary

Identifier

ORG-100049050

Address

Gyogy Ter 2, 8230, Hungary

Departments

2207 : Kardiológiai Osztály
Aktiv Kardiologia Osztaly
Cardiology
Cardiology Department
Cardiology Department I.
Kardiológiai osztály
n/a

Clinical trials at this site (9)

Search interface

An investigational trial to evaluate the effects of the drug XC001 delivered via a catheter in subjects with chronic angina caused by corona… Recruiting

2024-514874-36-01 Refractory angina due to obstructive coronary artery di 4 2026-04-17
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting

2025-521670-34-00 Acute coronary syndrome (ST-elevation myocardial infarc 5 2026-03-04
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting

2024-519917-72-00 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amy 5 2025-10-29
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia –… Ended

2023-504914-31-00 Hyperlipidaemia 11 2024-11-10
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Non-obstructive Hypertrophic Cardiomyopathy 5 2023-04-13
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 Symptomatic Obstructive Hypertrophic Cardiomyopathy 11